Original filing (PDF)20250720103144NAL0000637682001

AVP VACCINES, L.L.C.

Name: AVP VACCINES, L.L.C. — AVP VACCINES, L.L.C. EMPLOYEES PROFIT SHARING PLAN, Form 5500 (2024)
Creator: AVP VACCINES, L.L.C.

Form 5500-SF

FILING_RECEIVED

AVP VACCINES, L.L.C. EMPLOYEES PROFIT SHARING PLAN

401(k) retirement plan

Active participants

Accounts w/ balance

Plan assets (EOY)

$4.0M

Net assets (EOY)

$4.0M

Plan health score (directional)

/ 100

Grade A

Top-tier plan health

Directional indicator computed from public Form 5500 data — compliance, concentration, cost, vendor stack and participation. Not a fiduciary tool.

Compliance & disclosures

100

Concentration risk

Total plan cost

Vendor stack

100

Participation health

Decision-maker contacts

CFO / Head of HR / Benefits Manager — verified email + LinkedIn for AVP VACCINES, L.L.C..

Plan sponsor

Name

AVP VACCINES, L.L.C.

EIN

82-3915068

Address

470 NEW MILFORD AVENUE · ORADELL, NJ · 07649

Phone

(201) 967-9116

Industry

Professional & Technical Servicessee all

Plan administrator

Same as plan sponsor.

Plan characteristics

Plan number

001

Plan year

2024

Plan year begin

2024-01-01

Tax period

2024-12-31

Filed

2025-07-20

Pension benefit codes

2E · Profit-sharing

2J · 401(k) feature

3B · Covers self-employed individuals

3D · Pre-approved plan (master / prototype / VS)

Audit & trust (Schedule H)

Auditor

—

Trustee / custodian

—

Trustee phone

—

Small plan (5500-SF) — Schedule H data not available.

Service providers (Schedule C)

Small plans don't disclose service providers

Related plans

Similar-size Professional & Technical Services plans

SITES MEDIAL, LLC

SITES MEDICAL, LLC 401(K) PROFIT SHARING PLAN AND TRUST

$4.0M · 57 participants

ADVANCED DESIGN CONCEPTS, INC.

ADVANCED DESIGN CONCEPTS, INC. 401(K) PLAN

$4.0M · 19 participants

INTEGRATED BIOTHERAPEUTICS LLC

INTEGRATED BIOTHERAPEUTICS LLC 401(K) PROFIT SHARING PLAN & TRUST

$4.0M · 24 participants

GERMAN HISTORICAL INSTITUTE

GERMAN HISTORICAL INSTITUTE 401(K) PLAN

$4.0M · 17 participants

ROSE SALTER MEDICAL RESEARCH FOUNDATION